ストックスクリーナーアプリを入手
15.68
1.82%
-0.29
アフターアワーズ：
15.68
Monte Rosa Therapeutics Inc (GLUE) 最新ニュース
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 6.4%Here's Why - MarketBeat
Monte Rosa Therapeutics (GLUE) price target increased by 22.54% to 21.78 - MSN
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 4.8%Here's Why - MarketBeat
Squarepoint Ops LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Wedbush Remains a Buy on Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to S&P Biotechnology Select Industry Index - marketscreener.com
Is Monte Rosa Therapeutics Inc. stock supported by innovation pipelineOptions Play & AI Forecasted Entry/Exit Points - Улправда
Monte Rosa Therapeutics (GLUE) Price Target Increased by 22.54% to 21.78 - Nasdaq
How Monte Rosa Therapeutics Inc. stock reacts to inflationary pressuresGlobal Markets & Momentum Based Trading Ideas - Улправда
What margin trends mean for Monte Rosa Therapeutics Inc. stockJuly 2025 Setups & Community Verified Watchlist Alerts - Улправда
First Week of GLUE February 2026 Options Trading - Nasdaq
Price Action: How institutional buying supports Monte Rosa Therapeutics Inc. stock2025 Analyst Calls & Fast Gaining Stock Strategy Reports - DonanımHaber
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Monte Rosa reports positive phase 1/2 study results - MSN
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 6%Here's Why - MarketBeat
Assessing Monte Rosa Therapeutics After Its 162.4% Surge and DCF Implied Upside in 2025 - Yahoo Finance
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Rating of "Hold" by Brokerages - MarketBeat
Monte Rosa Therapeutics announces data from Phase 1/2 study of MRT-2359 - Yahoo Finance
Wells Fargo upgrades Monte Rosa Therapeutics (GLUE) - MSN
Wells Fargo Upgrades Monte Rosa Therapeutics (GLUE) - Nasdaq
GSPT1 chat favorable as Monte Rosa scores in prostate phase I/II - BioWorld MedTech
Why Is Monte Rosa Stock Trading Higher Today? - Benzinga
Monte Rosa reports promising results for MRT-2359 in prostate cancer - Investing.com Nigeria
Wedbush Adjusts Monte Rosa Therapeutics Price Target to $26 From $19, Maintains Outperform Rating - marketscreener.com
Monte Rosa Therapeutics (NASDAQ:GLUE) Sets New 52-Week HighShould You Buy? - MarketBeat
Monte Rosa Therapeutics (GLUE) Receives Analyst Upgrade and Pric - GuruFocus
Monte Rosa Therapeutics Says Advanced Prostate Cancer Combination Therapy Trial Shows 64% Disease Control - marketscreener.com
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Adjusts Price Target to $22 From $13 - marketscreener.com
Monte Rosa Reports Positive Phase 1/2 Study Results - TipRanks
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations - Investing News Network
Monte Rosa Therapeutics : Corporate Presentation – December 2025 - marketscreener.com
Monte Rosa Therapeutics Announces Positive Interim Data for MRT-2359 in Prostate Cancer - TradingView — Track All Markets
Monte Rosa Therapeutics (NASDAQ: GLUE) posts positive MRT-2359 Phase 1/2 data - Stock Titan
Monte Rosa Therapeutics announces compelling clinical activity of MRT-2359 in combination with enzalutamide - marketscreener.com
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results - The Manila Times
Monte Rosa Therapeutics to Host Conference Call on Interim Results of MRT-2359 for mCRPC Treatment - Quiver Quantitative
Monte Rosa (Nasdaq: GLUE) to share MRT-2359 mCRPC Phase 1/2 data Dec. 16 - Stock Titan
Franklin Resources Inc. Raises Stock Holdings in Monte Rosa Therapeutics, Inc. $GLUE - Defense World
Monte Rosa Therapeutics (NASDAQ:GLUE) Nasdaq Futures Biotech Momentum - Kalkine Media
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates - sharewise.com
GLUE Crosses Above Average Analyst Target - Nasdaq
Critical Survey: Monte Rosa Therapeutics (NASDAQ:GLUE) & Cogent Biosciences (NASDAQ:COGT) - Defense World
Piper Sandler Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Monte Rosa Therapeutics stock hits 52-week high at $16.66 By Investing.com - Investing.com India
Monte Rosa Therapeutics stock hits 52-week high at $16.66 - Investing.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st
Monte Rosa Therapeutics (GLUE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Improved Revenues Required Before Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock's 26% Jump Looks Justified - 富途牛牛
Monte Rosa: Looking Mispriced After Big Pharma Validation (NASDAQ:GLUE) - Seeking Alpha
Monte Rosa Therapeutics Jumps 124.9% in 2025 But Are Investors Getting Ahead of Themselves - Yahoo Finance
Hillsdale Investment Management Inc. Makes New $271,000 Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month HighShould You Buy? - MarketBeat
0.90%
大文字化:
|
ボリューム (24 時間):